Contract Pharma6d
Sanofi to Acquire DR-0201 from Dren Bio
Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...
PharmExec7d
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...
EconoTimes8d
Sanofi to Acquire Dren Bio’s Autoimmune Drug DR-0201 in $1.9B Deal
Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...
Sanofi to acquire Dren Bio’s DR-0201; deal includes $600M upfront payment
Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...
Pharmabiz7d
Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201
Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...
Nasdaq8d
Sanofi To Acquire Dren Bio's Myeloid Cell Engager DR-0201 For Upfront $600 Mln
(RTTNews) - Sanofi (SNY), a French pharmaceutical and healthcare company, announced on Thursday that it has entered into a definitive agreement to acquire Dren Bio, Inc.'s DR-0201, a targeted ...